- Summits
- Sponsorship
- Retreats
- Media Opportunities
- News
- About
Every breakthrough begins with someone asking a question no one else has answered.
Perhaps it’s a physician determined to improve patient outcomes. A scientist pursuing a promising molecule. A startup founder building an AI platform that could transform diagnostics. An entrepreneur developing the next generation of medical devices. An investor backing a technology capable of redefining an entire category of care.
In those early moments, optimism is abundant.
Then reality arrives.
For many promising companies, the greatest obstacle isn’t scientific failure—it’s the inability to navigate the business, regulatory and strategic complexity that stands between innovation and adoption.
The first investor asks difficult questions. Intellectual property must be protected. Regulatory pathways become more complex than anticipated. FDA requirements evolve. Reimbursement strategies suddenly matter as much as the science itself. Strategic partnerships emerge. Growth accelerates. New opportunities—and new risks—appear with every milestone.
What began as an innovation has become a journey through one of the world’s most dynamic and highly regulated industries.
The organizations that ultimately succeed are rarely those with the best technology alone. More often, they are the ones that align scientific innovation with business strategy, legal guidance, regulatory planning and commercialization from the very beginning.
That philosophy defines Cozen O’Connor‘s Health Care & Life Sciences Practice.
“We believe legal counsel should do more than mitigate risk—it should create momentum. Our multidisciplinary team partners with innovators throughout the business lifecycle—from company formation and financing through regulatory strategy, FDA matters, compliance, reimbursement, intellectual property, commercialization and strategic transactions, including exits,” says Angela Lupardus, Director of Business Development, Health Care & Life Sciences, Cozen O’Connor.
For many of today’s most innovative health care and life sciences companies, success doesn’t stop at national borders. A breakthrough developed in Europe often reaches its greatest potential when it successfully scales into the United States—the world’s largest and most dynamic health care market. But expanding across jurisdictions requires far more than understanding a new legal framework. It demands trusted advisors who understand the business landscape, regulatory environment, investment community and strategic relationships that help organizations grow with confidence.
“At Cozen O’Connor, we help clients build those bridges—connecting innovative companies with the legal guidance, industry insight and multidisciplinary network needed to develop a successful U.S. growth strategy,” says Angela.
“Recognizing that growth requires more than legal counsel alone, we’ve also integrated strategic relationships into our cultivated ecosystem that clients often benefit from,” she adds.
That integrated approach has helped clients achieve transformative milestones, including advising on a $100 million strategic partnership for a biotechnology company, defending health systems through complex government compliance investigations and guiding pharmaceutical innovators from FDA approval to successful commercial launch.
The next decade of health care will be defined by organizations that successfully integrate science, technology, capital, regulation and commercialization.
Innovation creates possibility.
Strategy creates momentum.
Execution changes lives.
“Cozen O’Connor’s Health Care & Life Sciences Practice is proud to help our clients navigate the path between breakthrough and impact.”
For MedTech companies serious about breaking into Asian markets, MedTech World Asia 2026 at the Hong Kong Convention and Exhibition Centre (26–28 August) is the right room. It brings together the region’s leading innovators, regulators, investors, and commercial decision-makers, and the host city makes it more than a conference. Hong Kong is the only city in Asia combining Western legal trust, direct China market access via CMDR 2026, GBA manufacturing reach, and a capital market with 1,500+ VC funds and the world’s #1 ranked exchange for biotech IPOs. If your Asia regulatory strategy is still taking shape, this is where it gets decided. Reserve your spot now.
